ONCAlert | Upfront Therapy for mRCC

Ovarian Cancer VIEW MORE >>

Treatment with an investigational targeted anti-cancer gene-therapy agent, VB-111, in addition to paclitaxel met the pre-specified efficacy criterion of an absolute percentage advantage of 10% or higher CA-125 response rate in patients with platinum-resistant ovarian cancer, according to results from the planned interim analysis of the phase III OVAL trial.
 

Latest JournalAll Journals >>

Targeted Therapies in Oncology November 2 2019
Targeted Therapies in Oncology
MORE >>
The Targeted Oncology ovarian cancer resource center provides the latest clinical updates about the disease state, with a plethora of ovarian cancer news articles covering the most up-to-date advancements in the field, as well as exclusive interviews with key ovarian cancer opinion leaders. Visitors to the site will find news that highlights both current and emerging ovarian cancer treatment options, as well as updates from the world’s most attended oncology conferences and annual meetings, including key coverage almost immediately after it is presented.

Additionally, video interviews and case studies from gynecologic oncologists and professionals specializing in ovarian cancer can be found on this page, offering expert guidance on the presentation of early ovarian cancer symptoms, tips and advice for management of the disease, and treatment options for patients. The web version of The Journal of Targeted Therapies, also found here, offers the most up-to-date data from recently completed clinical trials, analyses, and ongoing studies in patients in all stages of ovarian cancer.
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.